Comparison of homeopathic medicines composed of Taraxacum officinale and Lycopodium clavatum for treating cellular hepatocarcinoma
Main Article Content
Abstract
Homeopathy has been increasingly standing out for its proven clinical benefits and for providing a course of treatment with fewer side effects to patients, thus promoting a better quality of life for them. Homeopathic therapy can be used in different contexts and is an additional alternative for treating cancer patients in Integrative Medicine. Within this context, hepatocellular carcinoma has a high mortality rate and, in most cases, is diagnosed in advanced cases. Therefore, this study evaluated the in vitro efficacy of the association of the homeopathic medicines Taraxacum officinale and Lycopodium clavatum against HepG2 cells. For this purpose, cells were grown in 75 cm² flasks and then plated in 96-well plates. The treatment with Taraxacum D4 + Taraxacum D8 + Taraxacum D12 and Taraxacum D5 + Lycopodium D6 at concentrations of 20, 40, and 60 µL/mL was added to each well. After 48 hours of incubation in an oven at 37ºC, 5% CO2, cells were subjected to the cell viability test by MTT. A decrease in viability was observed compared to the control group (cells without treatment). In addition, the medicine Taraxacum officinale was more effective in decreasing cell viability than the other medicines in the three conditions tested. In conclusion, the homeopathic medicine Taraxacum D4 + Taraxacum D8 + Taraxacum D12, in accord of potencies, is promising against hepatocellular carcinoma cells and can be used to aid in the treatment of this type of cancer.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Träger-Maury S, Tournigand C, Maindrault-Goebel F, et al. Utilisation de médecine complémentaire chez les patients atteints de cancer dans un service de cancérologie français [Use of complementary medicine by cancer patients in a French oncology department]. Bull Cancer. 2007;94(11):1017-1025.
3. Amin Mir M, Sawhney SS, & Jassal MMS. Qualitative and quantitative analysis of phytochemicals of Taraxacum officinale. Wudpecker Journal of Pharmacy and Pharmocology, 2013;2(1), 1-5.
4. Singh A, Malhotra S, & Subban R. Dandelion (Taraxacum officinale)-hepatoprotective herb with therapeutic potential. Pharmacognosy Reviews, 2008; 2(3), 163.
5. Koo HN, Hong SH, Song BK, Kim CH, Yoo YH, Kim HM. Taraxacum officinale induces cytotoxicity through TNF-alpha and IL-1alpha secretion in Hep G2 cells. Life Sci. 2004; 74(9):1149-1157. doi:10.1016/j.lfs.2003.07.030
6. Di Napoli A, Zucchetti P. A comprehensive review of the benefits of Taraxacum officinale on human health. Bull Natl Res Cent 2021; 45, 110. doi: 10.1186/s42269-021-00567-1
7. Vannier L. Textbook of homeopathic medical matter. Ed. Andrey. 1987; 446p. Sao Paulo.
8. Wang B, Guan C & Fu Q. The traditional uses, secondary metabolites, and pharmacology of Lycopodium species. Phytochem 2022; Rev 21, 1–79. doi:10.1007/s11101-021-09746-4
9. Samadder A, Das S, Das J, Paul A, Boujedaini N, & Khuda-Bukhsh A R. The Potentized Homeopathic Drug, Lycopodium clavatum (5C and 15C) Has Anticancer Effect on HeLa Cells In Vitro. Journal of Acupuncture and Meridian Studies, 2013; 6(4), 180–187. doi: 10.1016/j.jams.2013.04.004
10. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, & Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 2021:71(3). doi: 10.3322/caac.21660
11. Nassan MA, Soliman MM, Ismail SA, El-Shazly S. Effect of Taraxacum officinale extract on PI3K/Akt pathway in DMBA-induced breast cancer in albino rats. Biosci Rep. 2018; 38(6):BSR20180334. Published 2018 Dec 21. doi:10.1042/BSR20180334
12. Menke K, Schwermer M, Felenda J, et al. Taraxacum officinale extract shows antitumor effects on pediatric cancer cells and enhance mistletoe therapy. Complement Ther Med. 2018;40:158-164. doi:10.1016/j.ctim.2018.03.005
13. Yamada N, Matsushima-Nishiwaki R, & Kozawa O. Quercetin suppresses the migration of hepatocellular carcinoma cells stimulated by hepatocyte growth factor or transforming growth factor-α: Attenuation of AKT signaling pathway. Archives of Biochemistry and Biophysics, 2020; 682, 108296. doi: 10.1016/j.abb.2020.108296
14. Nassan MA, Soliman MM, Ismail SA, El-Shazly S. Effect of Taraxacum officinale extract on PI3K/Akt pathway in DMBA-induced breast cancer in albino rats. Biosci Rep. 2018; 38(6):BSR20180334. Published 2018 Dec 21. doi:10.1042/BSR20180334
15. Ren F, Zhang Y, Qin Y, Shang J, Wang Y, Wei P, Guo J, Jia H, & Zhao T. Taraxasterol prompted the antitumor effect in mice burden hepatocellular carcinoma by regulating T lymphocytes. Cell Death Discovery, 2022; 8(1), 264. doi: 10.1038/s41420-022-01059-5
16. Pathak S, Bhattacharjee N, Das JK, Choudhury SC, Karmakar SR, Banerjee P, Paul S, Banerjee A, & Khuda-Bukhsh AR. Supportive evidence for the anticancerous potential of alternative medicine against hepatocarcinogenesis in mice. Forschende Komplementarmedizin 2007; 14(3), 148–156. doi: 10.1159/000103280
17. Giang VH, Thuy LT, Hanh TTH, Cuong NX, Vinh LB, Ban NK, Linh TM, Mai NC, Huong TT, Dang NH, Oh H, Lee DS, & Quang TH. Cytotoxic and nitric oxide inhibitory activities of triterpenoids from Lycopodium clavatum L. Natural Product Research, 2022; 36(24), 6232–6239. doi: 10.1080/14786419.2021.2024824
18. Samadder A, Das S, Das J, Paul A, Boujedaini N, Khuda-Bukhsh AR. The potentized homeopathic drug, Lycopodium clavatum (5C and 15C) has anticancer effect on hela cells in vitro. J Acupunct Meridian Stud. 2013;6(4):180-187. doi:10.1016/j.jams.2013.04.004